Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017;18:719–31. https://doi.org/10.1016/S1470-2045(17)30186-9
Article PubMed PubMed Central Google Scholar
Japanese Society of Pediatric Hematology/Oncology. Practical guidelines for pediatric cancer [In Japanese]. 2016. http://27.34.141.111/journal_en/guideline.html
Katanoda K, Shibata A, Matsuda T, Hori M, Nakata K, Narita Y, et al. Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. Jpn J Clin Oncol. 2017;47:762–71. https://doi.org/10.1093/jjco/hyx070
Article PubMed PubMed Central Google Scholar
GBD Childhood Cancer Collaborators. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017. Lancet Oncol. 2019;20:1211–25. https://doi.org/10.1016/S1470-2045(19)30339-0
Japanese Society of Pediatric Hematology/Oncology. Number of registered solid tumors by institution (2015), aggregation results of disease registration. 2015. http://27.34.141.112/disease_record.html
Barrett D, Fish JD, Grupp SA. Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. Pediatr Clin N Am. 2010;57:47–66. https://doi.org/10.1016/j.pcl.2010.01.001
Japanese Data Center for Hematopoietic Cell Transplantation/Japan Society for Hematopoietic Cell Transplantation. Hematopoietic cell transplantation in Japan, National Survey Report. 2019. http://www.jdchct.or.jp/data/report/2019/
Kondo E, Ikeda T, Goto H, Nishikori M, Maeda N, Matsumoto K, et al. Pharmacokinetics of thiotepa in high-dose regimens for autologous hematopoietic stem cell transplant in Japanese patients with pediatric tumors or adult lymphoma. Cancer Chemother Pharmacol. 2019;84:849–60. https://doi.org/10.1007/s00280-019-03914-2
Article CAS PubMed PubMed Central Google Scholar
Maanen MJ, Smeets CJ, Beijnen JH. Chemistry, pharmacology and pharmacokinetics of N,N’,N” -triethylenethiophosphoramide (ThioTEPA). Cancer Treat Rev. 2000;26:257–68. https://doi.org/10.1053/ctrv.2000.0170
Article CAS PubMed Google Scholar
Heideman RL, Cole DE, Balis F, Sato J, Reaman GH, Packer RJ, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: Evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49:736–41.
Shay H, Zarafonetis C, Smith N, Woldow I, Sun DC. Treatment of leukemia with triethylene thiophosphoramide (thio-TEPA); preliminary results in experimental and clinical leukemia. AMA Arch Intern Med. 1953;92:628–45. https://doi.org/10.1001/archinte.1953.00240230028004
Article CAS PubMed Google Scholar
Shay H, Sun DC. Clinical studies of triethylenethiophosphoramide in the treatment of inoperable cancer. Cancer. 1955;8:498–511. https://doi.org/10.1002/1097-0142(1955)8:3<498::aid-cncr2820080310>3.0.co;2-m
Article CAS PubMed Google Scholar
TEPADINA 15 mg powder for concentrate for solution for infusion (summary of product characteristics). ADIENNE S.r.l. S.U, Caponago, Italy; 2015. https://www.ema.europa.eu/en/documents/product-information/tepadina-epar-product-information_en.pdf
Kondo E. Primary central nervous system lymphoma: advances in treatment strategies [In Japanese]. Rinsho Ketsueki 2020;61:510–9. https://doi.org/10.11406/rinketsu.61.510
Suzuki R, Takahashi Y, Inoue M, Kanamori H, Hashii Y, Sakamaki H, et al. Thiotepa for autologous hematopoietic stem cell transplantation for solid tumors. Ann Oncol. 2015;26:vii140. https://doi.org/10.1093/annonc/mdv472.156
Nishiwaki S, Ando Y. Application of the new process for unapproved drug use: dilemma of universal health care coverage in Japan. J Glob Onco.l 2019;5:1–3. https://doi.org/10.1200/JGO.19.00313
Thiotepa 100 mg (RETHIO IV infusion) [Japanese package insert] Osaka, Japan: Sumitomo Pharma Co., Ltd.; 2022. https://pins.japic.or.jp/pdf/newPINS/00068017.pdf
Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. Int J Hematol. 2022;115:391–98. https://doi.org/10.1007/s12185-021-03263-y
Barton CD, Waugh LK, Nielsen MJ, Paulus S. Febrile neutropenia in children treated for malignancy. J Infect. 2015;71:S27–35. https://doi.org/10.1016/j.jinf.2015.04.026
Haeusler GM, Sung L, Ammann RA, Phillips B. Management of fever and neutropenia in paediatric cancer patients: Room for improvement? Curr Opin Infect Dis. 2015;28:532–8. https://doi.org/10.1097/QCO.0000000000000208
Article CAS PubMed Google Scholar
Bhuta R, Nieder M, Jubelirer T, Ladas EJ. The gut microbiome and pediatric cancer: current research and gaps in knowledge. J Natl Cancer Inst Monogr. 2019;2019:169–73. https://doi.org/10.1093/jncimonographs/lgz026
Secombe KR, Coller JK, Gibson RJ, Wardill HR, Bowen JM. The bidirectional interaction of the gut microbiome and the innate immune system: implications for chemotherapy-induced gastrointestinal toxicity. Int J Cancer. 2019;144:2365–76. https://doi.org/10.1002/ijc.31836
Article CAS PubMed Google Scholar
Valteau-Couanet D, Le Deley MC, Bergeron C, Ducassou S, Michon J, Rubie H, et al. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer 2014;61:977–81. https://doi.org/10.1002/pbc.24713
Article CAS PubMed Google Scholar
Epperla N, Li A, Logan B, Fretham C, Chhabra S, Aljurf M, et al. Incidence, risk factors for and outcomes of transplant-associated thrombotic microangiopathy. Br J Haematol. 2020;189:1171–81. https://doi.org/10.1111/bjh.16457
Article CAS PubMed PubMed Central Google Scholar
Caselli D, Rosati A, Faraci M, Podda M, Ripaldi M, Longoni D, et al. Risk of seizures in children receiving busulphan-containing regimens for stem cell transplantation. Biol Blood Marrow Transplant 2014;20:282–5. https://doi.org/10.1016/j.bbmt.2013.10.028
Article CAS PubMed Google Scholar
Vassal G, Deroussent A, Hartmann O, Challine D, Benhamou E, Valteau-Couanet D, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990;50:6203–7.
Wolff SN, Herzig RH, Fay JW, LeMaistre CF, Brown RA, Frei-Lahr D, et al. High-dose N,N’,N”-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: Phase I studies. Semin Oncol. 1990;17:2–6.
Weaver CH, Bensinger WI, Appelbaum FR, Lilleby K, Sandmaier B, Brunvand M, et al. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant. 1994;14:813–9.
Hara J, Osugi Y, Ohta H, Matsuda Y, Nakanishi K, Takai K, et al. Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone Marrow Transplant. 1998;22:7–12. https://doi.org/10.1038/sj.bmt.1701283
Article CAS PubMed Google Scholar
Okada K, Yamasaki K, Nitani C, Fujisaki H, Osugi Y, Hara J. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: a second report. Pediatr Blood Cancer. 2019;66:e27953 https://doi.org/10.1002/pbc.27953
Mason WP, Grovas A, Halpern S, Dunkel IJ, Garvin J, Heller G, et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol. 1998;16:210–21. https://doi.org/10.1200/JCO.1998.16.1.210
Article CAS PubMed Google Scholar
Altshuler C, Haley K, Dhall G, Vasquez L, Gardner SL, Stanek J, et al. Decreased morbidity and mortality of autologous hematopoietic transplants for children with malignant central nervous system tumors: the ‘Head Start’ trials, 1991-2009. Bone Marrow Transplant. 2016;51:945–8. https://doi.org/10.1038/bmt.2016.45
Article CAS PubMed Google Scholar
Cacchione A, LeMaitre A, Couanet DV, Benhamou E, Amoroso L, Simonnard N, et al. Risk factors for hepatic veno-occlusive disease: A retrospective unicentric study in 116 children autografted after a high-dose BU-thiotepa regimen. Bone Marrow Transplant. 2008;42:449–54. https://doi.org/10.1038/bmt.2008.186
Article CAS PubMed Google Scholar
Desai AV, Heneghan MB, Li Y, Bunin NJ, Grupp SA, Bagatell R, et al. Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma. Bone Marrow Transplant. 2016;51:1204–10. https://doi.org/10.1038/bmt.2016.84
Article CAS PubMed Google Scholar
Elborai Y, Hafez H, Moussa EA, Hammad M, Hussein H, Lehmann L, et al. Comparison of toxicity following different conditioning regimens (busulfan/melphalan and carboplatin/etoposide/melphalan) for advanced stage neuroblastoma: Experience of two transplant centers. Pediatr Transplant. 2016;20:284–9. https://doi.org/10.1111/petr.12638
Article CAS PubMed Google Scholar
Grill J, Kalifa C, Doz F, Schoepfer C, Sainte-Rose C, Couanet D, et al. A high-dose busulfan-thiotepa combination followed by autologous bone marrow transplantation in childhood recurrent ependymoma. A phase-II study. Pediatr Neurosurg. 1996;25:7–12. https://doi.org/10.1159/000121089
Article CAS PubMed Google Scholar
DeNunzio NJ, Yock TI. Modern radiotherapy for pediatric brain tumors. Cancers. 2020;12:1533. https://doi.org/10.3390/cancers12061533.
Kline CN, Mueller S. Neurocognitive outcomes in children with brain tumors. Semin Neurol. 2020;40:315–21. https://doi.org/10.1055/s-0040-1708867
Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. Lancet Oncol. 2004;5:399–408. https://doi.org/10.1016/S1470-2045(04)01507-4
Okada K, Soejima T, Sakamoto H, Hirato J, Hara J. Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy for children with newly diagnosed medulloblastoma: a report from the Japanese Pediatric Brain Tumor Consortium. Pediatr Blood Cancer. 2020;67:e28572. https://doi.org/10.1002/pbc.28572
Article CAS PubMed Google Scholar
Yamasaki K, Okada K, Soejima T, Sakamoto H, Hara J. Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: a prospective registry study in Japan. Pediatr Blood Cancer. 2020;67:e28012. https://doi.org/10.1002/pbc.28012
留言 (0)